Select acquires remainder of subsidiaries

By Melissa Trudinger
Tuesday, 30 November, 2004

Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.

The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.

Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.

The Lipid Network launched this month to build links between researchers, clinicians and industry...

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

Content from other channels on our network

Victoria announces "massive" upgrade to one of its busiest hospitals

NSW IRC decision prompts "mixed emotions" from nurses and midwives

Surgical robot expands its scope of procedures

Neuroscientists propose clinical definition for brain fog in menopause

National Pain Alliance launched to advocate for chronic pain

AI won’t restart your plant: Why practical skills matter more than ever

POSCO Holdings steps up HILT CRC partnership

Melbourne company gets funding for new battery manufacturing model

Hazer and KBR complete commercial-scale hydrogen plant design

Calibration explained: principles, processes and modern reporting

Community food network closes its soft plastics recycling loop

Real-time monitoring reduces risk at pumping station

Victorian oil refinery fire may impact fuel supply

Leafy greens identified as potential metal mining tools

Smart monitoring helps tram network cut water use by 70%